{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    10,
    23,
    27,
    29,
    41,
    50
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Treatment beyond progression criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.6",
        "sectionTitle": "Treatment beyond progression",
        "description": "Reference in Study Design synopsis regarding conditions for treating beyond disease progression"
      },
      {
        "id": "ref_2",
        "name": "Safety Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6",
        "sectionTitle": "Adverse Events",
        "description": "Reference to the full description of ongoing safety monitoring"
      },
      {
        "id": "ref_3",
        "name": "DMC Oversight Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Data Monitoring Committee",
        "description": "Reference to the establishment and oversight of the Data Monitoring Committee"
      },
      {
        "id": "ref_4",
        "name": "Phenomenon Evidence Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.6",
        "sectionTitle": "Introduction/Rationale",
        "description": "Reference to clinical evidence of disease progression before clinical objective response"
      },
      {
        "id": "ref_5",
        "name": "Sorafenib Survival Data Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.6.2",
        "sectionTitle": "Introduction/Rationale",
        "description": "Reference to data suggesting sorafenib administration beyond first radiological PD"
      },
      {
        "id": "ref_6",
        "name": "RECIST 1.1 Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "RECIST 1.1",
        "description": "Reference to investigator-assessed response criteria"
      },
      {
        "id": "ref_7",
        "name": "Correlative Studies Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.6.1",
        "sectionTitle": "Pharmacodynamic and Biomarker Assessments",
        "description": "Reference for tumor tissue correlative studies required for randomization"
      },
      {
        "id": "ref_8",
        "name": "Child-Pugh Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "CHILD-PUGH SCORE",
        "description": "Reference for cirrhotic status classification"
      },
      {
        "id": "ref_9",
        "name": "ECOG Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "ECOG PERFORMANCE STATUS",
        "description": "Reference for performance status scale"
      },
      {
        "id": "ref_10",
        "name": "Alpha Update Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.4.2.1",
        "sectionTitle": "Analysis of OS",
        "description": "Reference in Administrative Letter 04 regarding update to overall alpha"
      },
      {
        "id": "ref_11",
        "name": "Sorafenib Treatment Beyond Progression",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.5.3.4",
        "sectionTitle": "Treatment beyond progression",
        "description": "Reference to provisions for continuing sorafenib after progression"
      },
      {
        "id": "ref_12",
        "name": "Sorafenib Dose Modification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.5.3.3",
        "sectionTitle": "Treatment Interruption or Discontinuation Criteria for Sorafenib",
        "description": "Reference for management of suspected adverse drug reactions"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Subjects may be treated beyond disease progression under protocol-defined conditions. See Section 3.1.6",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Design",
        "pageNumber": 4
      },
      {
        "id": "annot_2",
        "text": "Fine needle aspiration (FNA) and bone metastases samples are not acceptable for submission",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "3.3.1 Inclusion Criteria",
        "pageNumber": 30
      },
      {
        "id": "annot_3",
        "text": "Refer to the sorafenib SmPC for additional details.",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.5.3.1 Sorafenib Dose and Schedule",
        "pageNumber": 51
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "04",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-01-15",
        "description": "Incorporates Amendment 18 and Administrative Letter 04. Updates guidance for nivolumab and adds exploratory objective for tumor inflammation.",
        "amendmentNumber": "18"
      },
      {
        "id": "ver_2",
        "versionNumber": "03",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-08-15",
        "description": "Incorporates Amendment 16 and Administrative Letters 02 and 03. Changes ORR to secondary objective.",
        "amendmentNumber": "16"
      },
      {
        "id": "ver_3",
        "versionNumber": "02",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-08-24",
        "description": "Incorporates Amendment 11. Co-primary endpoint changed from TTP to ORR.",
        "amendmentNumber": "11"
      },
      {
        "id": "ver_4",
        "versionNumber": "01",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-10-01",
        "description": "Incorporates Amendment 02. Addition of PBMC and MDSC collection.",
        "amendmentNumber": "02"
      }
    ],
    "summary": {
      "referenceCount": 12,
      "annotationCount": 3,
      "versionCount": 4
    }
  }
}